|
|
|
Provisional Agenda
Day 1 - Monday 1st September 2008
|
08:55 |
Chair Introduction
Advances in Tissue Engineering & Regenerative Medicine |
|
09:00 |
Epigenetic Manipulation of Stem Cells in Regenerative Medicine: Identification of Chromatin Targets for Interventions that Promote Muscle Regeneration
Pier Lorenzo Puri, Associate Telethon Scientist, Dulbecco Telethon Institute |
|
09:30 |
Mobilization of Unique Populations of Haematopoietic Progenitor Cells in Response to Clinical Situations Associated with Liver Regeneration
Dr Ursula Gehling, Head of Research Laboratory, University Hospital Hamburg |
|
10:00 |
Title to be Confirmed
Dr Magdi Yacoub, Professor, Imperial College |
|
10:30 |
Coffee and Networking in Main Exhibition Hall |
|
10:30 |
A Chemical Approach to Stem Cell Biology
Sheng Ding, Professor, Scripps Research Institute
This presentation will discuss identifications and mechanistic characterizations of small molecules that control self-renewal, differentiation, and reprogramming of various stem/progenitor cells. |
|
11:15 |
Embryonic Stem Cell-Derived Neurons as a Novel Cellular Model System to Study Neurodegenerative and Neuroregenerative Processes in Vitro
Dr Miriam Bibel, Senior Researcher, Novartis Institute for BioMedical Research |
|
11:45 |
Title to be Confirmed
Dr Louise Leong, Science Director, Stem Cells for Safer Medicine |
|
12:15 |
Lunch and Poster Presentations |
|
14:00 |
Key Note Presentation
Therapeutic and Research Potential of Human Stem Cells
Dr Stephen Minger, Professor, Kings College London
Progress in the fields of stem cell biology and regenerative medicine is accelerating rapidly. This talk with provide an overview of how different populations of human stem cells will and can be used in both a clinical and research setting. |
|
14:30 |
Key Note Presentation
Title to be Confirmed
Sir Ian Willmut, Centre for Regenerative Medicine, University of Edinburgh |
|
15:00
|
Title to be Confirmed
Dr Lorraine Young, Professor, Wolfson Centre for Stem Cells |
|
15:30 |
Coffee and Networking in Main Exhibition Hall |
|
16:15 |
Genetic Regulation of the Stem Cell Niche and the Outcome of Stem Cell Therapy in Blinding Ocular Surface Disease
Julie Daniels, Head of Department, UCL Institute of Ophthalmology
Corneal transparency and therefore vision is dependent upon the functionality of limbal epithelial stem cells (LESCs). The effect of haploinsufficiency of the eye development gene Pax6 on LESC functionality and the outcome of cultured LESC therapy in patients will be discussed |
|
16:45 |
Challenges and Opportunities Facing Stem Cell Commercialisation
Cathy Prescott, Director, Biolatris Ltd |
|
17:15 |
Stem Cell Space in Research and Regenerative Medicine
Enal Razvi, Biotechnology Analyst, Select Biosciences
This presentation will present snapshots from Select Biosciences continual industry coverage of the stem cell spaces for life science research, drug discovery, and regenerative medicine. Data from our worldwide market analyses are presented and framed in the context of the market opportunities in these segments. |
|
17:45 |
Drinks Reception |
Day 2 - Tuesday 2nd September 2008
|
08:55 |
Chair Introduction
|
|
09:00 |
Derivation of Germ Cell from Stem Cells
Dr Karim Nayernia, Chair of Stem Cell Biology, NESCI |
|
09:30 |
Flow Cytometric Set up and Challenges with Respect to Stem Cells
Dr Ian Dimmick, Flow Cytometry Manager , North East England Stem Cell Institute
Stem cells present unique challenges to anyone who wants to sort or analyse these cells. I will review the procedures we have in place to enable accurate and sensitive flow cytometry and sorting. |
|
10:00 |
Title to be Confirmed |
|
10:30 |
Coffee and Networking in the Main Exhibition Hall |
|
11:15 |
Induction of Immunologic Tolerance and Gerontoprotector Effects of Embryonic Progenitor Cell Transplantation in Rats and Mice
Mr Kukharchuk, Coordination Centre for Organ, Tissue and Cell Transplantation Ministry of Health, Ukraine |
|
11:45 |
Title to be Confirmed |
|
12:15 |
Lunch and Poster Presentations |
|
14:00 |
Human Mesenchymal Stem Cells Accelerate the Healing of Skin and Increase Intestinal Recovery after Radiation Injury
Dr Alain Chapel, Principal Investigator, Institute of Nuclear Safety |
|
14:30 |
Generation of Pluripotent Stem Cells from Adult Human Testis
Thomas Skutella, Director, University of Tuebingen |
|
15:00 |
Cancer Stem Cells: New Therapeutic Targets
Dr Dominique Bonnet, Senior Group Leader, Cancer Research UK |
|
15:30 |
Coffee and Networking in Main Exhibition Hall |
|
16:15 |
Title to be Confirmed |
|
16:45 |
Assay Strategies for the Identification of Small Molecule Modulators of Human Embryonic Stem Cells
Dr Hakim Djaballah, Director HTS Core Facility, Memorial Sloan-Kettering Cancer Center
This group has successfully screened a chemical library and identified several modulators of human embryonic stem cells; some of which induced differentiation and others simply maintained the cells in an undifferentiated state. |
|
17:15 |
Title to be Confirmed |
|
17:45 |
Close of Day 2 |
Day 3 - Wednesday 3rd September 2008
|
08:55 |
Session: Regulations, Intellectual Property and Commercialization
Chair: Enal Razvi, Biotechnology Analyst, Select Biosciences |
|
09:00 |
Development of Technology to Enhance the Growth of Cultured Stem Cells and Their Derivatives
Professor Stefan Przyborski, Director and Chief Scientific Officer, REInnervate |
|
09:30 |
Building an hES Cell Screening Capability: Fast Track to Cell Production
Dr Fergus McKenzie, ITI Life Sciences |
|
10:00 |
Terms of Engagement: Knowledge Transfer Between Industry and Academia
Jolyon White, Technnology Consultant, London Technology Network
LTN is a very active technology brokerage. In the last 3 years (2004 to 2007) the network has facilitated 840 deals worth over £35M. Using case studies from the company’s own activity in this field Jolyon will illustrate: - where the deal begins, the drivers for the relationship, the barriers to completion of the deal, the value of the relationship in the valorisation of the deal, that there is a role for a third party broker, deal maker or facilitator? |
|
10:30 |
Coffee and Networking |
|
11:00 |
Title to be Confirmed |
|
11:30 |
Keynote Presentation
Title to be Confirmed
Bernard Siegel, Executive Director, Genetics Policy Institute |
|
12:00 |
Moving Towards Becoming a Product-based Company
Johan Hyllner, Cellartis |
|
12:30 |
Lunch and Networking |
|
13:25 |
Session: Stem Cell Patentability
Chair: Dr Fergus McKenzie, ITI Life Sciences |
|
13:30 |
Stem Cell Patentability in the US, EU and Germany
Clara Sattler de Sousa e Brito, Researcher, Max Planck Institute for Intellectual Property, Competition and Tax Law
This presentation will provide an overview over the legal situation on the patentability of stem cells in the US, Europe and Germany in the light of the new technological and legal developments. |
|
14:00 |
Patentability of Embroynic Stem Cells
Philippa Montgomerie, Associate, DLA Piper Scotland LLP |
|
14:30 |
Coffee and Networking |
|
15:00 |
Tissue Engineered Products: Conditions for a Supportive Regulatory Environment
Laure Brevignon-Dodin, Research Associate, University of Cambridge
Regulatory differences and market fragmentation across member states have hampered the development of the tissue engineering industry in the EU. |
|
15:30 |
The Patentability of Stem Cell Inventions Under European Patent Law
Ingwer Koch, Director of Patent Law, European Patent Office |
|
16:00 |
IP Update: Patentability of Stem Cell Inventions in Europe
Nick Bassil, Patent Attorney, Kilburn and Strode
The IP landscape is a changeable and a potentially complex field, especially in relation to inventions in the field of stem cell technology. However, it need not be and there are simple points to understand which enable a clear path to be followed. The IP situation in Europe is under review and whatever the outcome of this process, interested parties need to be ready to adapt business strategies accordingly. Nick's presentation will focus on successful, cost-effective patenting strategies under the current law and with a view to the outcome of the review in Europe.
|
|
16:30 |
Panel Discussion |
|
17:00 |
Close of Conference | |